Jasper Therapeutics, Inc. (JSPR): Nasdaq/NYSE listing notice — Jasper Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

Jasper Therapeutics, Inc.

Nasdaq notice on Nov 3, 2022: bid price below $1.00 for 30 consecutive business days.
Company has 180 days (until May 2, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.
No immediate impact on listing; JSPR and JSPRW continue trading on Nasdaq Capital Market.
Options include reverse stock split if needed; company intends to monitor and consider available options.
Failure to cure may lead to delisting; possible appeal process but no assurance of relief.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 3, 2022, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until May 2, 2023, to regain compliance. The Not

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-069368

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.